4 Low-Beta Stocks for a Steadier Portfolio: LQDA, XOM, VLO & FANG
Middle East tensions are stoking volatility; a low-beta screen spotlights Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy.
LQDA - Liquidia Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$63.00
DETAILS
HIGH:
$67.00
LOW:
$60.00
MEDIAN:
$62.00
CONSENSUS:
$63.00
UPSIDE:
3.31%
Stock News
Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market.
Best Momentum Stocks to Buy for May 13th
LQDA, NEXA and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 13th, 2026.
New Strong Buy Stocks for May 13th
HCSG, NUE, NEXA, LQDA and NKSH have been added to the Zacks Rank #1 (Strong Buy) List on May 13th, 2026.
These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results
Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.
Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)
Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but further market share gains are likely capped by entrenched competitors and limited product differentiation. At a near $5 billion market cap and 9x run-rate revenue, the current valuation assumes sustained momentum and peak Yutrepia sales north of $1.2 billion, which appears optimistic.
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Liquidia Q1 Earnings Call Highlights
Liquidia NASDAQ: LQDA reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates
Liquidia Corporation (LQDA) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.45 per share a year ago.
Liquidia Corporation Reports First Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025 Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606 MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026.
Best Low-Beta Stocks to Own Right Away: LQDA, CBOE, VLO & FANG
Low beta screen highlights LQDA, CBOE, VLO and FANG as Middle East tensions keep U.S. stocks volatile, and investors favor steadier movers.
Liquidia Corporation to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences.
New Strong Buy Stocks for May 6th
INTT, EOG, UVE, LQDA and UMBF have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2026.
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026.
This Drug Stock Nears A Buy Point, With Profit Set To Explode
This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer its drug.
Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million
53,300 shares were sold indirectly for a transaction value of ~$2.14 million across April 14, 2026, to April 16, 2026, at a weighted average price of around $40.21 per share. Direct and indirect holdings are now at 1,137,599 and 1,441,934 shares, respectively.
Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells $1,003,500.00 in Stock
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,466,934 shares of the
Insider Selling: Liquidia (NASDAQ:LQDA) CFO Sells $5,595,114.60 in Stock
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) CFO Michael Kaseta sold 139,390 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total transaction of $5,595,114.60. Following the completion of the sale, the chief financial officer owned 353,356 shares of the
Price Targets
Liquidia price target raised to $67 from $55 at H.C. Wainwright
$67.00
(was $53.50)
Andrew Fein
·
H.C. Wainwright
Liquidia price target raised to $62 from $51 at Wells Fargo
$62.00
(was $53.13)
Wells Fargo
Liquidia price target raised to $60 from $57 at Jefferies
$60.00
(was $53.13)
Amy Li
·
Jefferies
Liquidia price target raised to $55 from $45 at Jefferies
$55.00
(was $37.02)
Amy Li
·
Jefferies
Liquidia price target raised to $50 from $35 at H.C. Wainwright
$50.00
(was $27.32)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $47 at Raymond James
$47.00
(was $25.22)
Ryan Deschner
·
Raymond James
Liquidia price target raised to $45 from $43 at Jefferies
$45.00
(was $25.22)
Jefferies
Liquidia downgraded to Underperform from Perform at Oppenheimer
$13.00
(was $17.03)
Andreas Argyrides
·
Oppenheimer
Liquidia price target raised to $36 from $34 at Scotiabank
$36.00
(was $16.12)
Greg Harrison
·
Scotiabank
Liquidia price target raised to $34 from $30 at Scotiabank
$34.00
(was $15.44)
Greg Harrison
·
Scotiabank
Liquidia named a top pick for 2025 at Needham
$19.00
(was $12.40)
Serge Belanger
·
Needham
Liquidia price target lowered to $23 from $24 at BofA
$23.00
(was $9.79)
Jason Gerberry
·
Bank of America Securities
Liquidia price target lowered to $17 from $22 at Jefferies
$17.00
(was $9.59)
Kambiz Yazdi
·
Jefferies
Liquidia upgraded to Strong Buy from Outperform at Raymond James
$27.00
(was $9.82)
Strong Buy
·
Raymond James
Liquidia Technologies (LQDA) PT Lowered to $23 at Jefferies
$23.00
(was $11.96)
Kambiz Yazdi
·
Jefferies
Needham Maintains Buy on Liquidia, Raises Price Target to $16
$16.00
(was $4.86)
Needham
Wedbush downgrades Liquidia to Underperform, lowers price target to $3
$3.00
(was $5.77)
Liana Moussatos
·
Wedbush
BTIG Maintains Buy on Liquidia, Raises Price Target to $17
$17.00
(was $5.42)
BTIG